In our next study, we will further investigate whether the targeted inhibition of PHLDB2 in combination with a PD-1 monoclonal antibody improves clinical outcomes in patients with head and neck squamous cell carcinoma. Here, PDCD1 is linked to head and neck squamous cell carcinoma.